Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 3.6 trillion in fiscal 2021. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geogr... Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 3.6 trillion in fiscal 2021. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada. Mostrar más
HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] is the First and Only Facilitated Subcutaneous Immunoglobulin (fSCIG) Approved in Japan for Agammaglobulinemia...
— US$10 million milestone payment to HUTCHMED follows first national reimbursement in Europe — — Follows June 2024 European approval of FRUZAQLA® (fruquintinib), the first novel oral targeted...
Six Late-Stage Programs with Peak Revenue Potential of $10B - $20B1 Poised to Deliver Sustainable Growth Expected Phase 3 Data Readouts in 2025 for Oveporexton (TAK-861), Zasocitinib (TAK-279...
− Elritercept is a late-stage, potentially best-in-class activin inhibitor designed to treat anemia associated with certain hematologic cancers, including myelodysplastic syndromes and...
— Launch follows approval by Japanese Ministry of Health, Labour and Welfare in September 2024 — — Milestone payment to be made to HUTCHMED from Takeda — — Fruquintinib already launched in several...
Umsatzwachstum von +13,4 % zu aktuellen Wechselkursen (AER); +5,0 % zu konstanten Wechselkursen (CER) Getrieben durch die kontinuierliche Weiterentwicklung von Wachstums- und...
Croissance du chiffre d’affaires de +13,4 % à taux de change réels (TCR) ; +5,0 % à taux de change constants (TCC) grâce à la progression continue des produits de croissance et de lancement...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will receive a...
売上収益は、実勢レート（AER：Actual Exchange Rate）ベースで対前年同期+13.4%、恒常為替レート（CER：Constant Exchange Rate）ベースで同+5.0%成長し、引き続き成長製品・新製品の伸長が牽引（CERベースで...
| Período † | Variación(Ptos) | Variación % | Apertura | Precio Máximo | Precio Mínimo | Avg. Vol. diario | Precio Promedio Ponderado | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.08 | 0.609756097561 | 13.12 | 13.32 | 13.04 | 1523060 | 13.17924508 | DR |
| 4 | -0.43 | -3.15480557594 | 13.63 | 14.04 | 12.98 | 1621955 | 13.44097769 | DR |
| 12 | -1.11 | -7.75681341719 | 14.31 | 14.43 | 12.98 | 1673920 | 13.69440579 | DR |
| 26 | 0.2 | 1.53846153846 | 13 | 15.08 | 12.95 | 1932101 | 13.94622006 | DR |
| 52 | -0.92 | -6.51558073654 | 14.12 | 15.08 | 12.575 | 1829275 | 13.93604401 | DR |
| 156 | -0.46 | -3.36749633968 | 13.66 | 17.15 | 12.28 | 2265154 | 14.52887334 | DR |
| 260 | -6.63 | -33.4341906203 | 19.83 | 20.6 | 12.28 | 2154421 | 15.42913683 | DR |
Monksdream
9 meses hace
Boing x 2
2 años hace
Phosphene
4 años hace
Phosphene
4 años hace
Phosphene
4 años hace
rising
7 años hace
rising
7 años hace
trendmkr
9 años hace
Parece que no se ha autenticado. Haga click al botón de abajo para iniciar la sesión y ver los símbolos recientemente consultados.
Soporte: (55) 4170 8128 | soporte@advfn.mx
Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones
Hot Features
Premium
